Hybridoma Technology

LakePharma's in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.                

Discovery Immunology mAbs can seamlessly transition to downstream GXP production, enabling one-stop shopping from discovery to development. 

A variety of proprietary immunization protocols (DNA, protein, peptide, small molecule, and cell-based) are available with demonstrated success in multiple wild-type murine strains and fully-human antibody-producing transgenic mice, with advanced tolerance-breaking approaches when needed (including use of specialized target-deficient mice).

ELISA- and FACS-based high-throughput screening and off-rate analyses of hybridomas indicate the specificity, cross-reactivity, and functionality of candidate antibodies as early as two months from campaign initiation.

Diverse therapeutic and clinical diagnostic/imaging candidates against immuno-oncology targets, GPCRs, neurobiology targets, enzymes, autoimmune/inflammatory targets, metabolic targets, and small molecules.

The workflow of Hybridoma Discovery Immunology

Complete campaigns incorporate LakePharma's unique suite of integrated services including:

• Target analysis and immunogen production
• Immunization, hybridoma generation, and single-cell cloning
• Variable region sequencing and purified mAb production/characterization 

Key Highlights

Chain of Discovery™
• Rigorous upfront target analysis and goal-oriented proposal development
• Data updates provide tracking from target to mAb delivery
• Delivery of sequence-confirmed hybridomas with variable region sequences

• Multiple wild-type mouse or rat strains 
• DNA, peptide, protein, and cell-based immunizations
• Often take multiple immunization approaches against a single target to generate a large diverse repertoire of candidate antibodies.

LakePharma's advanced tolerance-breaking approaches can open epitopic space for targets that are highly conserved between humans and mice. They can also increase opportunities for discovering cross-reactive antibodies or for generating surrogate anti-mouse target antibodies.

• Analysis of heavy and light chain V- and J- gene usage and of CDR3 sequence
• 384-well high-throughput ELISA or FACS screening of thousands of hybridomas for target binding
• Incorporation of cell-based ligand blocking assays
• ELISA, BLI, Carterra Arrayed SPR epitope binning and affinity determination

Proprietary PentaMice™ Platform for Maximum Plasma Titers 
• Royalty-free set of wildtype mice designed for in vivo immunizations to achieve maximum plasma titers 
• The platform consists of 5 WT strains that cover 9 distinct MHC haplotypes
• 10 mice total (2 mice per strain) are included 

Client Testimonial: Tri-Institutional Therapeutics Discovery Institute and LakePharma: A Partnership in Antibody Discovery to Enable Innovative Therapeutics

Download a free eBookIntroduction to Hybridoma Technologies for Antibody Discovery

PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery webinar recording available NOW

Discovery of Potent, Functional Anti-BTLA, and Anti-TIGIT Monoclonal Antibodies using Hybridoma and Phage Display Platform webinar recording available NOW!

Download our Antibody Discovery & Engineering Services Brochure by clicking here

Download our Pentamice Flyer by clicking here.

"LakePharma is nothing short of a true partner with Apollos Diagnostics. We will continue to work with LakePharma as a partner for all of our future antibody development campaigns."

- John Alderete, Ph.D., MBA; Founder and President of Folium Biomed, LLC
View the testimonial here

"LakePharma is a great partner to work with. Their expertise enables them to generate large panels of antibodies that can be used as the foundation for our therapeutic candidates"

Ronald Herbst, Ph.D., CSO, Pyxis Oncology

View Pyxis clinical pipeline

"LakePharma was a great partner; very helpful, focused, and committed. Thank you for your antibody engineering and production services which made this project a success."

- Maria Day, ImmuNext

View their press release here